Nascent Biotech Inc (NBIO)

$0.00 0.00 (-25.00%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 10,100
Avg Vol 55,056
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 29%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and t...

Industry: Biotechnology
Sector: Healthcare
Phone: 612 961 5656
Address:
631 US Hwy 1, Suite 407, North Palm Beach, United States
4sprouts
4sprouts Jul. 5 at 5:49 PM
$NBIO 1. https://www.nascentbiotech.com/message-from-senior-management/ 2. https://www.nascentbiotech.com/letter-to-shareholders-from-sean-carrick/
0 · Reply
J1983
J1983 May. 9 at 2:46 PM
$NBIO @ok2buy The .0001 gives you hope? It’s over, my friend. We had our chance and should’ve sold years ago when it hit .45. I’ll always regret not selling.
0 · Reply
ok2buy
ok2buy May. 7 at 5:21 PM
$NBIO Nope. Don't believe this is done./
1 · Reply
J1983
J1983 May. 3 at 6:49 PM
$NBIO @4sprouts I don’t think this is good news at all for NBIO and us investors: “The CHO derived antibody discussed here is considered a new antibody and an IND has been approved by the FDA to commence dose-esclation clinical trial will be evaluated.” This is a new FDA approved antibody based off PTB. Makes sense why NBIO has given up. Write it off as a loss, it’s over.
1 · Reply
4sprouts
4sprouts May. 2 at 10:24 PM
$NBIO pritumumab was featured in the medical journal Nature in March 2025. It included contributing author Santosh Kesari, medical consultant and equity holder in Nascent Biotech. Hopefully there will be renewed interest in bringing pritumumbab into active Phase II trials and continue to demonstrate its potential. Would be nice to hear from the company with future course of action. Open access Published: 25 March 2025 Characterization of pritumumab in murine models and primate safety study https://www.nature.com/articles/s41598-025-95360-9
0 · Reply
J1983
J1983 Apr. 29 at 8:08 PM
$NBIO Who’s been buying at .03?
1 · Reply
ok2buy
ok2buy Apr. 23 at 6:37 PM
$NBIO I have a significant amount of shares on this one. And nothing from management. My holdings pale in comparison to at least 5 investors here who own millions of shares and are out a sizeable investment. I hope they are active and want their money back.
0 · Reply
synaphai
synaphai Apr. 3 at 10:54 PM
$NBIO In case anybody didn't see, Sean filed to deregister the company's shares and either terminate or suspend the duty to file. EDGAR isn't even acknowledging the NBIO ticker anymore, to see the filing you have to search for the company name. So I guess that's it for the hope of publicly trading again. Not sure what's going to happen to pritumumab. I sent a message to SAVA, a company with cash but a failed drug, suggesting pritumumab as an option but they probably got tons of those types of emails. I haven't been invested in NBIO in years because of Sean but would love to see the drug eventually get the chance to finally prove itself after getting abandoned in Japan and now here. Current investors have my sympathy.
0 · Reply
ok2buy
ok2buy Mar. 21 at 6:39 PM
$NBIO Management, still no action? Restore compliance or sell the asset!!
0 · Reply
jkrowleens
jkrowleens Feb. 11 at 8:36 PM
$NBIO Nascent Biotech Inc. (OTCQB) $INAB IN8bio, Inc. (Nasdaq: INAB),
0 · Reply
Latest News on NBIO
No data available.
4sprouts
4sprouts Jul. 5 at 5:49 PM
$NBIO 1. https://www.nascentbiotech.com/message-from-senior-management/ 2. https://www.nascentbiotech.com/letter-to-shareholders-from-sean-carrick/
0 · Reply
J1983
J1983 May. 9 at 2:46 PM
$NBIO @ok2buy The .0001 gives you hope? It’s over, my friend. We had our chance and should’ve sold years ago when it hit .45. I’ll always regret not selling.
0 · Reply
ok2buy
ok2buy May. 7 at 5:21 PM
$NBIO Nope. Don't believe this is done./
1 · Reply
J1983
J1983 May. 3 at 6:49 PM
$NBIO @4sprouts I don’t think this is good news at all for NBIO and us investors: “The CHO derived antibody discussed here is considered a new antibody and an IND has been approved by the FDA to commence dose-esclation clinical trial will be evaluated.” This is a new FDA approved antibody based off PTB. Makes sense why NBIO has given up. Write it off as a loss, it’s over.
1 · Reply
4sprouts
4sprouts May. 2 at 10:24 PM
$NBIO pritumumab was featured in the medical journal Nature in March 2025. It included contributing author Santosh Kesari, medical consultant and equity holder in Nascent Biotech. Hopefully there will be renewed interest in bringing pritumumbab into active Phase II trials and continue to demonstrate its potential. Would be nice to hear from the company with future course of action. Open access Published: 25 March 2025 Characterization of pritumumab in murine models and primate safety study https://www.nature.com/articles/s41598-025-95360-9
0 · Reply
J1983
J1983 Apr. 29 at 8:08 PM
$NBIO Who’s been buying at .03?
1 · Reply
ok2buy
ok2buy Apr. 23 at 6:37 PM
$NBIO I have a significant amount of shares on this one. And nothing from management. My holdings pale in comparison to at least 5 investors here who own millions of shares and are out a sizeable investment. I hope they are active and want their money back.
0 · Reply
synaphai
synaphai Apr. 3 at 10:54 PM
$NBIO In case anybody didn't see, Sean filed to deregister the company's shares and either terminate or suspend the duty to file. EDGAR isn't even acknowledging the NBIO ticker anymore, to see the filing you have to search for the company name. So I guess that's it for the hope of publicly trading again. Not sure what's going to happen to pritumumab. I sent a message to SAVA, a company with cash but a failed drug, suggesting pritumumab as an option but they probably got tons of those types of emails. I haven't been invested in NBIO in years because of Sean but would love to see the drug eventually get the chance to finally prove itself after getting abandoned in Japan and now here. Current investors have my sympathy.
0 · Reply
ok2buy
ok2buy Mar. 21 at 6:39 PM
$NBIO Management, still no action? Restore compliance or sell the asset!!
0 · Reply
jkrowleens
jkrowleens Feb. 11 at 8:36 PM
$NBIO Nascent Biotech Inc. (OTCQB) $INAB IN8bio, Inc. (Nasdaq: INAB),
0 · Reply
AVCTQBNAPL
AVCTQBNAPL Feb. 11 at 4:37 PM
$NBIO https://finance.yahoo.com/news/in8bio-reports-updated-positive-results-130000659.html
0 · Reply
AVCTQBNAPL
AVCTQBNAPL Feb. 11 at 4:37 PM
$NBIO https://finance.yahoo.com/news/in8bio-reports-updated-positive-results-130000659.html
0 · Reply
AVCTQBNAPL
AVCTQBNAPL Feb. 11 at 4:36 PM
$NBIO https://finance.yahoo.com/news/in8bio-reports-updated-positive-results-130000659.html
0 · Reply
AVCTQBNAPL
AVCTQBNAPL Feb. 11 at 4:34 PM
$NBIO https://finance.yahoo.com/news/in8bio-reports-updated-positive-results-130000659.html.
1 · Reply
AVCTQBNAPL
AVCTQBNAPL Feb. 11 at 4:34 PM
$NBIO 🍾🥂🚀 https://finance.yahoo.com/news/in8bio-reports-updated-positive-results-130000659.html.
0 · Reply
AVCTQBNAPL
AVCTQBNAPL Feb. 11 at 4:34 PM
$NBIO 🚀🚀🚀 https://finance.yahoo.com/news/in8bio-reports-updated-positive-results-130000659.html.
1 · Reply
4sprouts
4sprouts Feb. 8 at 12:03 AM
$NBIO Only update is their 8k filing updated 1/17/25- Independent director Mr. Karas is stepping down for health reasons; the Directors and Officers of the Company agreed to terminate the non- dilutive stock clause in their employment contacts; & The Company is assessing the value of the QB verses pink reporting and the cost difference on the OTC- Stockholders need more information on the direction of the company: https://app.quotemedia.com/data/downloadFiling?webmasterId=102691&ref=318850481&type=HTML&symbol=NBIO&cdn=2d9a847256b403f3f97080a05b9daf7f&companyName=Nascent+Biotech+Inc&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2025-01-17
1 · Reply
ZaDoctor
ZaDoctor Feb. 5 at 12:56 AM
$NBIO This dude needs to speak up - https://www.linkedin.com/in/seanpcarrick/
1 · Reply
ok2buy
ok2buy Feb. 4 at 1:52 PM
$NBIO Management, still nothing???
0 · Reply
morealpha
morealpha Jan. 31 at 6:30 PM
$NBIO almost back to a penny…
0 · Reply
Laylos
Laylos Jan. 31 at 2:40 AM
$NBIO how did management let this happen...
0 · Reply
ok2buy
ok2buy Jan. 27 at 6:55 PM
$NBIO Thought you guys were fixing this debacle?
0 · Reply